Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma

被引:1
作者
Kim, Younghoon [1 ,2 ,3 ]
Song, Jaewon [4 ]
Kim, Namkyoung [2 ]
Sim, Taebo [1 ,2 ,3 ,4 ,5 ]
机构
[1] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, 145 Anam Ro, Seoul 02841, South Korea
[2] Yonsei Univ, Dept Biomed Sci, Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea
[3] Yonsei Univ, Clin Candidate Discovery & Dev Inst, Coll Med, Seoul, South Korea
[4] Yonsei Univ, Grad Sch Clin Drug Discovery & Dev, Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea
[5] Yonsei Univ, Grad Sch Med Sci, Brain Korea 21 Project, Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
BILIARY-TRACT CANCER; ISOCITRATE DEHYDROGENASE 1; STRUCTURE-BASED DESIGN; POSITIVE SOLID TUMORS; CELL LUNG-CANCER; MUTANT IDH1; SELECTIVE INHIBITOR; KINASE INHIBITION; OPEN-LABEL; ACQUIRED-RESISTANCE;
D O I
10.1039/d4md00881b
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholangiocarcinoma (CCA) is a diverse group of epithelial malignant tumors arising from the biliary tract, characterized by high molecular heterogeneity. It is classified into intrahepatic (iCCA) and extrahepatic CCA (eCCA) based on the location of the primary tumor. CCA accounts for approximately 15% of all primary liver cancers, with iCCA comprising 10-20% of all CCAs. iCCA is especially known for its characteristic aggressiveness and refractoriness, leading to poor prognosis. Despite the increasing global incidence and mortality rates, surgery remains the only available standard treatment approach for a subset (25%) of patients with early-stage, resectable iCCA. The paucity of effective systemic medical therapies restricts therapeutic options for patients with advanced or metastatic iCCA. In the past decade, advances in the understanding of the molecular complexity of these tumors have provided fruitful insights for the identification of promising new druggable targets and the development of feasible therapeutic strategies that may improve treatment outcomes for patients with iCCA. In this review, we aim to highlight critical up-to-date studies and medicinal chemistry aspects, focusing on novel targeted approaches utilizing promising candidates for molecular targeted therapy in iCCA. These candidates include aberrations in isocitrate dehydrogenase (IDH) 1/2, fibroblast growth factor receptor (FGFR), B-Raf proto-oncogene (BRAF), neurotrophic tyrosine receptor kinase (NTRK), human epidermal growth factor receptor 2 (HER2), and programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1). Furthermore, this review provides an overview of potential inhibitors aimed at overcoming acquired drug resistance in these actionable targets for iCCA.
引用
收藏
页码:2314 / 2359
页数:47
相关论文
共 256 条
[1]   Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].
Abou-Alfa, Ghassan K. ;
Macarulla, Teresa ;
Javle, Milind M. ;
Kelley, Robin K. ;
Lubner, Sam J. ;
Adeva, Jorge ;
Cleary, James M. ;
Catenacci, Daniel V. ;
Borad, Mitesh J. ;
Bridgewater, John ;
Harris, William P. ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Whisenant, Jonathan ;
Lowery, Maeve A. ;
Goyal, Lipika ;
Shroff, Rachna T. ;
El-Khoueiry, Anthony B. ;
Fan, Bin ;
Wu, Bin ;
Chamberlain, Christina X. ;
Jiang, Liewen ;
Gliser, Camelia ;
Pandya, Shuchi S. ;
Valle, Juan W. ;
Zhu, Andrew X. .
LANCET ONCOLOGY, 2020, 21 (06) :796-807
[2]   High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer [J].
Ahn, Soomin ;
Lee, Jong-chan ;
Shin, Dong Woo ;
Kim, Jaihwan ;
Hwang, Jin-Hyeok .
SCIENTIFIC REPORTS, 2020, 10 (01)
[3]   Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? [J].
Aitcheson, Gabriella ;
Mahipal, Amit ;
John, Binu, V .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (04) :463-477
[4]  
Ali S., 2013, Patent No. [WO2010078421A1, 2010078421]
[5]   Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities [J].
Andersen, Jesper B. ;
Thorgeirsson, Snorri S. .
GASTROENTEROLOGY, 2013, 144 (04) :687-690
[6]   Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations [J].
Hyman, David M. ;
Puzanov, Igor ;
Subbiah, Vivek ;
Faris, Jason E. ;
Chau, Ian ;
Blay, Jean-Yves ;
Wolf, Juergen ;
Raje, Noopur S. ;
Diamond, Eli L. ;
Hollebecque, Antoine ;
Gervais, Radj ;
Elena Elez-Fernandez, Maria ;
Italiano, Antoine ;
Hofheinz, Ralf-Dieter ;
Hidalgo, Manuel ;
Chan, Emily ;
Schuler, Martin ;
Lasserre, Susan Frances ;
Makrutzki, Martina ;
Sirzen, Florin ;
Veronese, Maria Luisa ;
Tabernero, Josep ;
Baselga, Jose .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) :726-736
[7]   Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma [J].
Arai, Yasuhito ;
Totoki, Yasushi ;
Hosoda, Fumie ;
Shirota, Tomoki ;
Hama, Natsuko ;
Nakamura, Hiromi ;
Ojima, Hidenori ;
Furuta, Koh ;
Shimada, Kazuaki ;
Okusaka, Takuji ;
Kosuge, Tomoo ;
Shibata, Tatsuhiro .
HEPATOLOGY, 2014, 59 (04) :1427-1434
[8]   PrognostA±c Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree [J].
Ata, Alper ;
Polat, Ayse ;
Serinsoz, Ebru ;
Sungur, Mehmet Ali ;
Arican, Ali .
PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (03) :831-838
[9]   Advances and challenges in targeting FGFR signalling in cancer [J].
Babina, Irina S. ;
Turner, Nicholas C. .
NATURE REVIEWS CANCER, 2017, 17 (05) :318-332
[10]   Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer [J].
Bahcall, Magda ;
Sim, Taebo ;
Paweletz, Cloud P. ;
Patel, Jyoti D. ;
Alden, Ryan S. ;
Kuang, Yanan ;
Sacher, Adrian G. ;
Kim, Nam Doo ;
Lydon, Christine A. ;
Awad, Mark M. ;
Jaklitsch, Michael T. ;
Sholl, Lynette M. ;
Jaenne, Pasi A. ;
Oxnard, Geoffrey R. .
CANCER DISCOVERY, 2016, 6 (12) :1334-1341